GLP-1 drugs are u003ca href=u0022#can-i-use-my-fsa-for-semaglutide-or-tirzepatideu0022u003eFSA eligibleu003c/au003e when they are prescribed to treat a diagnosed medical condition, not cosmetic weight loss
spokeswoman for the corporation, stressed that Wegovy remains the only anti-obesity GLP-1 approved for adolescent weight loss, and only then as a once-weekly injection
The compound is currently being studied in the Phase 3 TRIUMPH clinical trial program, with primary readouts actively emerging
Fiber supplementation addresses constipation
[18] Other research suggests that several pharmaceutical companies, including AstraZeneca, Zealand Pharma, Roche, and Amgen, are expected to enter the GLP-1 market, with multiple drug launches planned between 2027 and 2032
report palpitations